Poley participate in clinical trials studying new combination drugs for wet and dry macular degeneration, diabetic macular edema and retinal vein occlusion. He continues to make newer therapies available to our patients as he and Dr. His dedication to innovative treatments such as anti-VEGF therapies for age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion has led to FDA approval of multiple drugs for these conditions. Marcus’ established the clinical trial unit at Southeast Retina Center which made now established therapies available to our patients prior to their approval to the general patient population. Marcus has brought cutting edge clinical therapies to our region as lead investigator in multiple clinical trials. He is recognized nationally as leader in vitreoretinal surgery, clinical retinal research, teaching and laboratory investigation. Marcus is devoted to the care of patients with diseases of the macula, retina and vitreous including age-related macular degeneration, diabetic retinopathy, and retinal detachment. Marcus has been treating patients at the Southeast Retina Center full time since 2005.ĭr. ![]() ![]() ![]() Marcus served as Director of the Retina Service at the Medical College of Georgia in Augusta from 1994-2005 where he was a tenured Professor of Ophthalmology, Vice-Chairman and recipient of the Outstanding Young Faculty Award. His 6 years of Harvard Medical School training included a research fellowship in ophthalmic pathology/ocular oncology, ophthalmology residency, and surgical fellowship in vitreoretinal surgery. Marcus came to Augusta after extensive training at the Massachusetts Eye and Ear Infirmary, Harvard Medical School in Boston. Marcus has been practicing vitreoretinal surgery in the CSRA since 1994 and is the owner and managing physician of Southeast Retina Center.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |